Vitamin D in blood and risk of prostate cancer: Lessons from the Selenium and vitamin E cancer prevention trial and the prostate cancer prevention trial

Cancer Epidemiology Biomarkers and Prevention

Volumn 23, Issue 8, 2014, Pages 1447-1449

  Schwartz, Gary G ^a,b  

^a WAKE FOREST BAPTIST HEALTH   (United States)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

25 HYDROXYVITAMIN D; PROSTATE SPECIFIC ANTIGEN; ALPHA TOCOPHEROL; SELENIUM; VITAMIN D;

AFRICAN AMERICAN; CANCER MORTALITY; CANCER RISK; CANCER SCREENING; DISEASE SEVERITY; GLEASON SCORE; HUMAN; LIGHT EXPOSURE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; REVIEW; SUNLIGHT; VITAMIN BLOOD LEVEL; BLOOD; MALE; PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIAL (TOPIC);

HUMANS; MALE; PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SELENIUM; VITAMIN D; VITAMIN E;

EID: 84905436021     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-14-0520     Document Type: Review

References (23)

1. Prostate cancer incidence and mortality trends in 37 European countries: an overview. Eur J Cancer 2010;46:3040-52.
2. Schwartz GG, Hulka BS. Is vitamin D deficiency a risk factor for prostate cancer? (Hypothesis) Anticancer Res 1990;10:1307-11.
3. Hanchette CL, Schwartz GG. Geographic patterns of prostate cancer mortality: evidence for a protective effect of ultraviolet radiation. Cancer 1992;70:2861-9.
4. Miller GJ, Stapelton GE, Ferrara JA, Lucia MS, Pfister S, Hedlund TE, et al. The human prostatic carcinoma cell line LNCaP expresses biologically active, specific receptors for 1a25-dihydroxyvitamin D3. Cancer Res 1992;52:515-20.
5. Schwartz GG, Whitlach LW, Chen TC, Lokeshwar B, Holick MF. Human prostate cells synthesize 1, 25-dihydroxyvitamin D3 from 25-hydroxyvitamin D3. Cancer Epidemiol Biomarkers Prev 1998;7:391-5.
6. Krishan AV, Feldman D. Molecular pathways mediating the antinflammatory effects of calcitriol: implications for prostate cancer chemoprevention and treatment. Endocr Relat Cancer 2010;17:R19-39.
7. Carlberg C, Molnar F. Current status of vitamin D signaling and its therapeutic implications. Curr Top Med Chem 2012;12:525-47.
8. Deeb KK, Trump DL, Johnson CS. Vitamin D signaling pathways in cancer: potential for anticancer therapies. Nat Rev Cancer 2007;7:684-700.
9. Grant WB. An estimate of premature cancer mortality in the U. S. due to nadequate doses of solar ultraviolet B-radiation. Cancer 2002;94:1867-75.
10. Bosco FP, Schymura MJ. Solar ultraviolet-B exposure and cancer incidence and mortality in the United States, 1993-2002. BMC Cancer 2006;10:264.
11. Schwartz GG, Hanchette CL. UV, latitude, and prostate cancer mortality: all sunlight is not the same (United States). Cancer Cause Control. 2006;17:1091-101.
12. John EM, Koo J, Schwartz GG. Sun exposure and prostate cancer risk: evidence for a protective effect of early life exposure. Cancer Epidemiol Biomarkers Prev 2007;16:1283-6.
13. Rukin N, Blagojevic M, Luscombe CJ, Liu S, Saxby MR, Ramachandran S, et al. Associations between timing of exposure to ultraviolet radiation, T-stage and survival in prostate cancer. Cancer Detect Prev 2007;31:443-9.
14. Lin SH, Wheller D, Yikung P, Cahoon E, Hollenbeck A, Freedman D, et al. Prospective study of ultraviolet radiation exposure and risk of cancer in the U. S. Int J Cancer 2012;131:E1015-123.
15. Schwartz GG. Vitamin D, sunlight, and the epidemiology of prostate cancer. Anticancer Agents Med Chem 2013;13:45-57.
16. Carter HB, Partin AW, Walsh PC, Trock BJ, Veltri RW, Nelson WG, et al. Gleason Score 6 adenocarcinoma: should it be labeled as cancer? J Clin Oncol 2012;30:4294-6.
17. Albertsen PC, Hanley JA, Fine J. 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA 2005;293:2095-101.
18. Kristal AR, Till C, Song X, Tangen CM, Goodman PJ, Neuhauser ML, et al. Plasma vitamin D and prostate cancer risk: results from the Selenium and Vitamin E Cancer Prevention Trial. Cancer Epidemiol Biomarkers Prev 2014;23:1494-504.
19. Lawson KA, Wright ME, Subar A, Hollenbeck A, Sahtzkin A, Leitzman MF. Multivitamin use and risk of prostate cancer in the National Institutes of Health AARP Diet and Health Study. J Natl Cancer Inst 2007;99:754-64.
20. Ginde AA, Liu MC, Camargo CA Jr. Demographic differences and trends of vitamin D insufficiency in the US population, 1988-2004. Arch Intern Med 2009;169:626-32.
21. Zadshir A, Tareen N, Pan D, Norris K, Martins D. The prevalence of hypovitaminosis D among US adults: data from the NHANES III. Ethn Dis 2005;15 (4 Suppl 5):S5-91-101.
22. Schenk JM, Till CA, Tangen CM, Goodman PJ, Song X, Torkko KC, et al. Serum 25-hydroxyvitamin D concentrations and risk of prostate cancer: results from the Prostate Cancer Prevention Trial. Cancer Epidemiol Biomarkers Prev 2014;23:1484-93.
23. Richter M, Otte D, Pohlemann T, Krettek C, Blauth M. Whiplash-type neck distortion in restrained car drivers: frequency, causes and longterm results. Eur Spine J 2000;9:109-17.